

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Tuesday, April 28, 2026
Time: 10:00 am Eastern Time
Location: Zoom Teleconference
Institution: Northside Hospital, Atlanta, GA
Principal Investigator: Melhem Solh, MD
Protocol: Poseida Therapeutics, Inc., P-BCMA-ALLO1-001
NCT Number: NCT04960579
Meeting Type: Continuing Review of Protocol and Site
Title: Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

1. Call to order:

The Meeting was called to order at 10:15 am Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for P-BCMA-ALLO1, since it consists of primary human cells modified using a plasmid and mRNA. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of P-BCMA-ALLO1 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. An Institutional Representative confirmed that biohazardous waste is temporarily stored underneath a countertop in the HSC Laboratory and then stored in the Biohazard Waste Storage room.
2. An Institutional Representative confirmed that a revised Site Map with an annotation where the temporary biohazardous waste storage bins are stored underneath the counter in the HSC Laboratory was recently submitted to IBC Services.
3. An Institutional Representative confirmed this study agent and other similar study agents, except for one, are prepared in the room near the dosing rooms. The Committee determined that the Biosafety SOPs are acceptable as written.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 10:20 am Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Protocol, Amendment 5, dated 09-11-2025

Investigator's Brochure, Edition 5, dated 11-18-2025

Cellular Therapy Lab and Administration Manual, Version 7, dated 09-08-2025

Biological Risk Assessment and Summary, updated 12-05-2025

Research Modification Evaluation, Protocol, Amendment 5

Research Modification Evaluation, Investigator's Brochure, Edition 5

Research Modification Evaluation, Cellular Therapy Lab and Administration Manual, Version 7

Site Map, BMT Unit, 4th Floor, dated 01-29-2024

Site Map, HSC Laboratory, dated 01-29-2024

Site Inspection Checklist, GMHC, expires 01-29-2028, updated 04-17-2026

Site Inspection Checklist, Autoclave Addendum, expires 04-20-2028

Photos, HSC Lab, BMT Unit, dated 04-23-2026

Biohazard Sign, Genetically Modified Human Cells, dated 04-20-2026

Biological Safety Cabinet Certifications, HSC Lab, expire 06-2026

SOP, Biosafety for Genetically Modified Human Cells, dated 04-20-2026

SOP Addendum, Biosafety for Allogeneic Cells, dated 04-20-2026

Training, Shipping Certification, expires 04-2026, 01-2028

CRRF, dated 01-05-2026

Prior Meeting Minutes, Initial, dated 04-22-2025